TickerGuard
Buy Day today: Poor (57) Mixed market breadth · today: Nonfarm Payrolls (September)
RNA

Atrium Therapeutics, Inc.

Healthcare · Biotechnology

8.10$ -1.8% vs. previous close Closing price · As of: Oct 1, 2026

Statements

Income Statement

Atrium Therapeutics, Inc. (RNA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 3.0 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement RNA
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
2.8 2.2 3.5 2.0 2.3 3.0 1.6 3.8 12 0.9 20 3.0 36
48 0.6 0.6 0.7 0.7 0.7 – 138 – 1.5 0.2 0.3 –
-45 1.6 2.9 1.4 2.3 3.0 1.6 -134 12 0.9 19 2.7 35
48 53 67 64 77 96 99 138 155 18 17 15 205
14 16 14 21 23 28 34 37 5.8 30 20 10 67
14 68 80 84 100 124 133 37 8.5 49 37 25 119
-59 -67 -77 -83 -98 -121 -132 -171 -8.5 -48 -17 -23 -96
– 0.4 – – – – – – – – – – –
-52 -60 -69 -71 -80 -102 -116 -157 -8.5 -48 -17 -20 -93
-6.3 0.0 0.6 – – – – – -0.2 0.0 – – –
-52 -60 -69 -71 -80 -102 -116 -157 -8.3 -48 -17 -20 -93
-58 -66 -77 -82 -97 -120 -131 -170 -8.4 -48 -16 -22 -95

LTM = last twelve months (sum of the four most recent quarters).

Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?